Signatera test

DEVICE2 trials

Sponsors

NRG Oncology, NSABP Foundation Inc

Conditions

Colon CancerStage III Colon Cancer

Phase 2

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

RecruitingNCT05174169

NRG OncologyStage III Colon Cancer

Start: 2022-03-10End: 2030-03-10Target: 1912Updated: 2026-04-02

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

WithdrawnNCT05178576

NSABP Foundation IncColon Cancer

Start: 2022-06-24End: 2027-02-28Updated: 2022-11-04

Related Papers

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America).

Journal of Clinical Oncology2026-01-10

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.

Journal of Clinical Oncology2025-05-28

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America).

Journal of Clinical Oncology2025-01-272 citations

Value of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial)

BMJ Open2025-01-011 citations

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.

Journal of Clinical Oncology2024-06-011 citations

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).

Journal of Clinical Oncology2024-01-205 citations

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology2023-06-011 citations

NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology2023-01-24

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

ONCOLOGY2022-10-1234 citations

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology2022-06-013 citations